PlumX Metrics
Embed PlumX Metrics

Leader cells promote immunosuppression to drive ovarian cancer progression in vivo

Cell Reports, ISSN: 2211-1247, Vol: 43, Issue: 11, Page: 114979
2024
  • 0
    Citations
  • 0
    Usage
  • 0
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Mentions
    1
    • News Mentions
      1
      • 1

Most Recent News

OCRF: Fostering careers of ovarian cancer researchers

Sponsored by: In Australia, one person dies from ovarian cancer every 8 hours. There are no tools for prevention, no early detection or accurate screening

Article Description

Over 75% of patients with ovarian cancer present with late-stage disease, often accompanied by extensive metastasis. The metastatic cascade is driven by a sub-population of transcriptionally plastic cells known as "leader cells" (LCs), which play a critical role in collective invasion yet remain poorly understood. LCs are marked by the expression of keratin-14 (KRT14), which determines their migratory and invasive capacity in ovarian cancer. This study demonstrates that KRT14+ LCs promote tumor progression through immunosuppression and immune privilege in vivo. In the ID8 syngeneic epithelial ovarian cancer mouse model, tumor-specific loss of KRT14+ LCs impairs tumor progression and metastatic spread without affecting cellular proliferation. Immune profiling shows reduced immunosuppressive regulatory T cells (Tregs) and M2 macrophages and improved CD8 + T cell/Treg ratios in LC knockout (LC KO ) mice. Conversely, forced LC overexpression accelerates metastasis and increases the secretion of immunosuppressive chemokines, such as CCL22 and CCL5, highlighting the role of KRT14+ LCs in immune suppression and metastatic progression.

Bibliographic Details

Wilson, Amy L; Moffitt, Laura R; Doran, Brittany R; Basri, Bashira; Do, Jennie; Jobling, Thomas W; Plebanski, Magdalena; Stephens, Andrew N; Bilandzic, Maree

Elsevier BV

Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know